Drug intelligence / Profile preview

CS91

Development stage: Preclinical
Modality: Small Molecules

Overview

CS91 is a novel nitroxide-functionalized prednisolone hybrid designed to enhance the efficacy of chemotherapy, specifically cisplatin, in cervical cancer. It acts as a dual-action agent by binding to the glucocorticoid receptor (GR) and modulating the cellular redox state. Mechanistically, CS91 increases intracellular reactive oxygen species (ROS) and depletes glutathione (GSH) levels, leading to increased DNA damage and potent anti-proliferative effects in cervical squamous cell carcinoma (SCC) cells. This redox-active hybrid is intended to overcome chemoresistance and reduce the dose-dependent toxicity associated with standard cisplatin treatment.

Other names: nitroxide-functionalised prednisolone hybrid

Targets

GSH (Glutathione)GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on CS91.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CS91.

Explore the full profile